Key Points
- Artivion SVP Andrew Green sold 44,001 shares on June 11 at an average price of $20.70, generating about $910,821. The sale reduced his direct ownership by 42.2% and was made under a pre-arranged Rule 10b5-1 plan.
- Artivion shares recently traded near $20.98, close to their 52-week low of $19.16 and well below the 52-week high of $48.25. The company has a market cap of about $1.02 billion and a high P/E ratio of 87.42.
- Wall Street remains broadly positive on AORT, with seven Buy ratings and one Sell rating, giving the stock a consensus Moderate Buy rating and an average price target of $46.17. However, some analysts have recently lowered price targets, and Weiss Ratings downgraded the stock to Sell.
Artivion, Inc. (NYSE:AORT - Get Free Report) SVP Andrew Green sold 44,001 shares of the firm's stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total value of $910,820.70. Following the completion of the transaction, the senior vice president directly owned 60,259 shares in the company, valued at approximately $1,247,361.30. This represents a 42.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Artivion Price Performance
Shares of Artivion stock opened at $20.98 on Tuesday. Artivion, Inc. has a one year low of $19.16 and a one year high of $48.25. The stock's fifty day moving average is $28.66 and its 200 day moving average is $36.79. The stock has a market cap of $1.02 billion, a P/E ratio of 87.42 and a beta of 1.27. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.80 and a current ratio of 3.86.
Wall Street Analyst Weigh In
AORT has been the topic of a number of recent research reports. LADENBURG THALM/SH SH raised Artivion from a "neutral" rating to a "buy" rating and set a $42.00 target price on the stock in a report on Friday, April 10th. Needham & Company LLC cut their price target on Artivion from $58.00 to $44.00 and set a "buy" rating for the company in a research note on Friday, May 8th. Weiss Ratings lowered Artivion from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Monday, June 8th. Citizens Jmp cut their price target on Artivion from $53.00 to $48.00 and set a "market outperform" rating for the company in a research note on Friday, May 8th. Finally, Stifel Nicolaus set a $45.00 price target on Artivion in a research note on Monday, June 1st. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $46.17.
Get Our Latest Stock Report on AORT
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in AORT. Royal Bank of Canada grew its position in shares of Artivion by 107.0% during the first quarter. Royal Bank of Canada now owns 38,707 shares of the company's stock valued at $952,000 after purchasing an additional 20,010 shares in the last quarter. AQR Capital Management LLC grew its position in shares of Artivion by 8.8% during the first quarter. AQR Capital Management LLC now owns 35,053 shares of the company's stock valued at $862,000 after purchasing an additional 2,823 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Artivion by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,591 shares of the company's stock valued at $580,000 after purchasing an additional 1,032 shares in the last quarter. Creative Planning grew its position in shares of Artivion by 5.6% during the second quarter. Creative Planning now owns 14,272 shares of the company's stock valued at $444,000 after purchasing an additional 753 shares in the last quarter. Finally, Invesco Ltd. grew its position in shares of Artivion by 40.8% during the second quarter. Invesco Ltd. now owns 481,026 shares of the company's stock valued at $14,960,000 after purchasing an additional 139,370 shares in the last quarter. Hedge funds and other institutional investors own 86.37% of the company's stock.
About Artivion
(
Get Free Report)
Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.
Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
